Ocular Drug Delivery Routes & Systems

Overview

Route selection turns on two questions: which anatomic compartment needs the drug (ocular surface and anterior segment versus vitreous and retina), and how much systemic exposure is acceptable. Topical administration gives the highest local concentration in the anterior segment for the least systemic absorption of any route, so it remains the default for anterior-segment disease. Subconjunctival, sub-Tenon, suprachoroidal, and intravitreal injection each place drug progressively deeper, or closer to the posterior segment, trading a more invasive procedure for direct access to tissue that topical drops cannot reach. Knowing which barrier a given route crosses, and which it doesn't, explains both its intended use and its characteristic side effects.

Topical Delivery and Its Barriers

The first barrier a topical drug meets is the corneal epithelium. Its tight junctions make the epithelium a lipophilic barrier, so lipid-soluble drugs cross most readily. Many ophthalmic agents are therefore formulated as prodrugs, or with penetration-enhancing excipients, to raise corneal uptake. Even a well-penetrating drug reaches intraocular tissue at strikingly low efficiency: typically 1–5% or less of the instilled dose, with the rest lost to tear dilution, reflex tearing, and above all nasolacrimal drainage. Drainage carries unabsorbed drug into the nasal mucosa, where it is absorbed rapidly into the systemic circulation and bypasses first-pass hepatic metabolism. This is the mechanistic basis for systemic side effects from locally applied drops, most notably topical beta-blockers (see Autonomic & Pupil Pharmacology and Anti-Glaucoma Pharmacology).

Two practical techniques exploit the same drainage pathway. Punctal occlusion, digital pressure at the medial canthus for 1–2 minutes after instillation, reduces drainage into the nasolacrimal system and lowers systemic absorption, which matters for agents like timolol. The conjunctival sac at rest holds only about 7–10 microliters, while a standard eye drop delivers 20–50 microliters, so a second drop instilled immediately washes the first one out before it can be absorbed. Spacing multiple topical medications at least 5 minutes apart avoids this washout.

Preservatives are a separate concern from the active drug. Benzalkonium chloride (BAK), a quaternary ammonium compound and the most common preservative in multi-dose formulations, disrupts the tear film and is directly toxic to corneal and conjunctival epithelial cells and goblet cells with chronic exposure. It is a meaningful contributor to ocular surface disease in patients on multiple long-term drops, classically glaucoma patients dosing several agents daily.

Injectable and Periocular Routes

Intravitreal injection places drug directly into the vitreous cavity and achieves concentrations at the posterior pole (retina and choroid) that topical or systemic routes cannot approach. It is the standard route for anti-VEGF agents, corticosteroids, and antibiotics targeting posterior-segment disease. Because the needle breaches the globe, the most important measure against post-injection endophthalmitis is 5% povidone-iodine applied to the conjunctival surface and fornices beforehand, which lowers surface bacterial load more than any other studied measure. See Antimicrobial & Antiviral Therapy for the fuller endophthalmitis prophylaxis and treatment regimen.

Suprachoroidal injection (for example, triamcinolone acetonide via microneedle) targets a different compartment, the potential space between sclera and choroid, from which drug distributes along the chorioretinal surface. It concentrates drug in the posterior segment while largely sparing the anterior chamber, which lowers the cataract and IOP-elevation risk of an intravitreal corticosteroid depot and minimizes systemic absorption.

Subconjunctival injection deposits drug beneath the conjunctiva, from where it diffuses through the sclera to the anterior uvea and anterior chamber, with only limited posterior-segment penetration. It suits perioperative corticosteroids and antibiotics but does not substitute for intravitreal delivery when the retina is the target. Sub-Tenon (periocular) injection deposits corticosteroid near the posterior sclera and is sometimes preferred over intravitreal injection in uveitis. The reason is not higher vitreous concentration, which it does not achieve, but avoidance of the endophthalmitis and cataract risk of a direct intraocular injection. That trade-off matters most in phakic eyes and bilateral disease, where an intravitreal steroid depot's cataractogenic risk is harder to accept.

Intracameral injection places antibiotic, most often moxifloxacin or cefuroxime, directly into the anterior chamber at the end of cataract surgery. The drug bypasses the corneal and conjunctival barriers entirely, so this route reaches anterior-chamber concentrations that topical or subconjunctival prophylaxis alone cannot match. Large multicenter studies have found a significant drop in postoperative endophthalmitis with intracameral antibiotic compared to topical antibiotic alone, and it is now standard practice at many cataract surgery centers. Because the drug lands in the target compartment directly rather than diffusing in from outside the globe, as sub-Tenon or subconjunctival injection do, protection begins almost immediately.

The Blood-Retinal Barrier

The blood-retinal barrier (BRB) is the retinal analog of the blood-brain barrier and has two structurally distinct components. The inner BRB is formed by tight junctions between retinal capillary endothelial cells; the outer BRB is formed by tight junctions between retinal pigment epithelium (RPE) cells. Both barriers must be considered together when designing any drug intended to reach the outer retina or subretinal space from the systemic circulation, since a drug that crosses one may still be excluded by the other.

The BRB also governs intravitreal drug clearance. In a normal phakic, non-vitrectomized eye, the intact vitreous gel retards diffusion and slows clearance of an injected drug. Anti-VEGF agents like ranibizumab have a vitreous half-life of roughly 7–9 days, which sets the typical 4–8 week re-injection interval used clinically. Clearance runs substantially faster in aphakic, pseudophakic, or vitrectomized eyes, where the gel that normally retards diffusion is absent or disrupted. The effective duration of an intravitreal drug is correspondingly shorter, and clinicians account for this when treating such eyes.

Sustained-Release and Implant Systems

Repeated intravitreal injection produces a peak-trough concentration pattern, with high drug levels immediately after injection declining toward the next dose. Sustained-release systems smooth this out. Sustained-release intravitreal implants such as fluocinolone acetonide deliver drug at a controlled, near-constant rate over an extended period, some formulations lasting up to 36 months. They hold therapeutic vitreous concentrations without peak-trough cycling and cut how often the patient needs a procedure.

The Port Delivery System (PDS) with ranibizumab takes a distinct approach to anti-VEGF therapy. Rather than a biodegradable implant that eventually dissolves, it is a permanent, surgically placed, refillable reservoir in the pars plana that continuously releases ranibizumab, reducing the treatment burden to a refill procedure roughly every 24 weeks for eligible patients with neovascular AMD. That pharmacokinetic profile differs from both bolus injection and a dissolving implant. See Anti-VEGF Therapy for the pharmacokinetics of the anti-VEGF agents themselves.

Sustained release isn't confined to the vitreous. The dexamethasone intracanalicular insert is placed through the punctum into the canaliculus at the end of cataract or corneal surgery. It swells to anchor itself and releases a tapered dose of dexamethasone over roughly 30 days before fully dissolving. Because the surgeon places it rather than the patient administering drops, it sidesteps the adherence problems that come with tapering a topical steroid at home.

Emerging Delivery Technologies

Nanoparticle delivery systems (liposomes, polymeric nanoparticles, dendrimers) aim to improve on the poor bioavailability of conventional drops. They increase ocular-surface residence time through mucoadhesion, protect the encapsulated drug from tear-protease degradation, and in some designs release drug in a controlled or tissue-targeted way rather than by bulk absorption.

Gene therapy for inherited retinal disease, the prototype being voretigene neparvovec (Luxturna) for RPE65-mutation-associated disease, is usually delivered by subretinal injection. The AAV vector is placed directly into the potential space between the photoreceptor outer segments and the RPE. This route transduces the target populations, RPE and photoreceptors, with a specificity that a vitreous or systemic route cannot match.

Related Topics

Continue exploring Basic Sciences: